Atorvastatin fails to slow atherosclerosis in pediatric SLE

10/27/2011 |

A study of 221 patients aged 10 to 21 years old with pediatric systemic lupus erythematosus found that taking atorvastatin for three years had no significant effect on subclinical atherosclerosis progression. Researchers failed to find any significant differences in progression of mean-mean common carotid intima-media thickening between those who took atorvastatin and those on placebo, but found reduced high-sensitivity C-reactive protein, low-density lipoprotein and total cholesterol levels in the statin group. The findings appear in the journal Arthritis & Rheumatism.

View Full Article in:

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL